Glenmark Pharmaceuticals Ltd— BUY—255—INR
Sector — Pharmaceuticals (Bulk drugs & Formulations)
Regd.Off.— 22, Bhulabhai Desai Road, Mumbai, 400026
Listed — NSE, BSE.
Company Overview—
Glenmark Pharmaceuticals Limited was incorporated in the year 1977. Glenmark is an India-based one of the fastest growing pharmaceutical company headquartered at Mumbai. Glenmark has built a visible and growing branded generic formulation presence across all its markets in Asia, Africa and CIS countries. A number of its products have emerged as brand leaders in India and these markets. Company is focused on the manufacture and marketing of formulation products and active pharmaceutical ingredients in India as well as globally and enjoys a diversified and growing presence in regulated and developing international markets. Over the past five years, the Company has also catalyzed its growth through investment in dedicated research and development including cutting-edge New Chemical Entity research. Company operates in over 75 markets for formulations and also supplies Active pharmaceutical ingredients to over 50 markets worldwide. Glenmark has strengthened its integration across the pharmaceutical value chain through operations across its various manufacturing plants, i.e. for formulations at Baddi, Goa, Nasik and Sao Paolo (Brazil) for API in Ankleshwar, Kurkumbh and Solapur. The Ankleshwar plant acquired from GlaxoSmithKline has received US FDA acceptance while the API manufacturing facilities at Kurkumbh and Solapur focus on supplying intermediates and APIs to less regulated markets. Company also acquired an ANVISA approved formulations facility in Brazil.
Products & Services—
Glenmark Pharmaceuticals Limited focuses on manufacturing and marketing formulation products within India. Glenmark made a foray into the bulk drug business in 2001. Today, it has generic formulation and API business interests in over 65 countries across the world including the highly regulated markets of USA and Europe. The formulation business spans several product segments such as Dermatology, Internal Medicine, Pediatrics, Gynecology, ENT and Diabetes. Company's business segment portfolio broadly comprises of both formulation and bulk drug sales. Company follows a branded generic model in markets across Asia, Africa, CIS/Russia and Latin America. In contrast, in the highly regulated markets of USA and Europe, the company has adopted a business model of registering and marketing generic drugs. The Bulk Drugs or API business for Glenmark handles the sales and marketing of active pharmaceutical ingredients to customers in many markets across the globe and also serves some of the captive needs of the formulations business within the company.
Formulations: Glenmark's formulation business has invested in building a manufacturing footprint to cater to the demand. The current footprint includes - One WHO-GMP plant at Nasik to cater to semi-regulated markets including India. The plant handles several dosage forms including liquids, solids, semi-solids and dry powders. A plant at Goa built to USFDA and EU standards. The plant has capabilities to manufacture tablets, capsules and ointments/creams. Another one ANVISA approved manufacturing plant in Brazil to cater to Latin American markets. This plant has capabilities in solids, liquids and semi-solids. In India, the company markets about 100 molecules/combinations spanning a diverse set of therapy segments. Over 50 of these molecules/combinations are also being marketed across the semi-regulated markets of Asia, Africa, Russia/CIS countries; more products are under registration in these markets. In formulations, Company is focusing working on Anti-diabetics, Respiratory Tract Infections, Cardiovascular, Pain & Anti-Inflammation, Dermatology, Gynecology, Internal medicine, and Pediatrics etc.
Active Pharmaceuticals ingredients— Active pharmaceutical ingredients (API), which are used as raw material in the manufacture of formulations, are the building blocks in the pharmaceutical industry. Company’s R&D center in Navi Mumbai employs over 350 scientists who have a vast experience across several disciplines and technology platforms. The research activities encompass process engineering for APIs, new chemical entity research and novel drug delivery systems. Company also operates a second research facility at Sinnar, near Nasik in India that focuses on developing formulations for India and markets across Asia, Africa, Latin America and CIS/Russia. Glenmark is amongst the few Indian Pharmaceutical Companies to have taken initiative to invest proactively in original drug discovery research.
Recent News—
On 22 jan, Glenmark Generics, USA, a subsidiary of Glenmark Pharmaceutical has received tentative approval by the United States Food and Drug Administration (USFDA) for Trandolapril and Verapamil hydrochloride extended-release tablets, its generic version of Abbott’s Tarka® tablets. Glenmark’s current marketing portfolio consists of 49 products authorized for distribution in the United States and it has nearly 50 ANDAs in various stages of the approval process with the USFDA.
On 2 mar, Glenmark Generics, (GGI) USA, a subsidiary of Glenmark Generics (GGL), has received ANDA approval from the United States Food and Drug Administration (USFDA) for Ropinirole Hydrochloride tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg and 5 mg. Ropinirole Hydrochloride tablet is the generic version of GSK’s Requip® tablet in the US market. Total sales for Ropinirole Hydrochloride tablets in the twelve month period ending December 2009 were USD 104 million, as reported by IMS Health.
Valuation—
At current market price, stock is trading at 11.74 P/E multiple of its FY2011 Estimated earnings. We recommend investors to buy "Glenmark Pharmaceuticals limited" for medium term investment horizon.
Source: Internet (Valuenotes by Abhishek Jain)
Sector — Pharmaceuticals (Bulk drugs & Formulations)
Regd.Off.— 22, Bhulabhai Desai Road, Mumbai, 400026
Listed — NSE, BSE.
Company Overview—
Glenmark Pharmaceuticals Limited was incorporated in the year 1977. Glenmark is an India-based one of the fastest growing pharmaceutical company headquartered at Mumbai. Glenmark has built a visible and growing branded generic formulation presence across all its markets in Asia, Africa and CIS countries. A number of its products have emerged as brand leaders in India and these markets. Company is focused on the manufacture and marketing of formulation products and active pharmaceutical ingredients in India as well as globally and enjoys a diversified and growing presence in regulated and developing international markets. Over the past five years, the Company has also catalyzed its growth through investment in dedicated research and development including cutting-edge New Chemical Entity research. Company operates in over 75 markets for formulations and also supplies Active pharmaceutical ingredients to over 50 markets worldwide. Glenmark has strengthened its integration across the pharmaceutical value chain through operations across its various manufacturing plants, i.e. for formulations at Baddi, Goa, Nasik and Sao Paolo (Brazil) for API in Ankleshwar, Kurkumbh and Solapur. The Ankleshwar plant acquired from GlaxoSmithKline has received US FDA acceptance while the API manufacturing facilities at Kurkumbh and Solapur focus on supplying intermediates and APIs to less regulated markets. Company also acquired an ANVISA approved formulations facility in Brazil.
Products & Services—
Glenmark Pharmaceuticals Limited focuses on manufacturing and marketing formulation products within India. Glenmark made a foray into the bulk drug business in 2001. Today, it has generic formulation and API business interests in over 65 countries across the world including the highly regulated markets of USA and Europe. The formulation business spans several product segments such as Dermatology, Internal Medicine, Pediatrics, Gynecology, ENT and Diabetes. Company's business segment portfolio broadly comprises of both formulation and bulk drug sales. Company follows a branded generic model in markets across Asia, Africa, CIS/Russia and Latin America. In contrast, in the highly regulated markets of USA and Europe, the company has adopted a business model of registering and marketing generic drugs. The Bulk Drugs or API business for Glenmark handles the sales and marketing of active pharmaceutical ingredients to customers in many markets across the globe and also serves some of the captive needs of the formulations business within the company.
Formulations: Glenmark's formulation business has invested in building a manufacturing footprint to cater to the demand. The current footprint includes - One WHO-GMP plant at Nasik to cater to semi-regulated markets including India. The plant handles several dosage forms including liquids, solids, semi-solids and dry powders. A plant at Goa built to USFDA and EU standards. The plant has capabilities to manufacture tablets, capsules and ointments/creams. Another one ANVISA approved manufacturing plant in Brazil to cater to Latin American markets. This plant has capabilities in solids, liquids and semi-solids. In India, the company markets about 100 molecules/combinations spanning a diverse set of therapy segments. Over 50 of these molecules/combinations are also being marketed across the semi-regulated markets of Asia, Africa, Russia/CIS countries; more products are under registration in these markets. In formulations, Company is focusing working on Anti-diabetics, Respiratory Tract Infections, Cardiovascular, Pain & Anti-Inflammation, Dermatology, Gynecology, Internal medicine, and Pediatrics etc.
Active Pharmaceuticals ingredients— Active pharmaceutical ingredients (API), which are used as raw material in the manufacture of formulations, are the building blocks in the pharmaceutical industry. Company’s R&D center in Navi Mumbai employs over 350 scientists who have a vast experience across several disciplines and technology platforms. The research activities encompass process engineering for APIs, new chemical entity research and novel drug delivery systems. Company also operates a second research facility at Sinnar, near Nasik in India that focuses on developing formulations for India and markets across Asia, Africa, Latin America and CIS/Russia. Glenmark is amongst the few Indian Pharmaceutical Companies to have taken initiative to invest proactively in original drug discovery research.
Recent News—
On 22 jan, Glenmark Generics, USA, a subsidiary of Glenmark Pharmaceutical has received tentative approval by the United States Food and Drug Administration (USFDA) for Trandolapril and Verapamil hydrochloride extended-release tablets, its generic version of Abbott’s Tarka® tablets. Glenmark’s current marketing portfolio consists of 49 products authorized for distribution in the United States and it has nearly 50 ANDAs in various stages of the approval process with the USFDA.
On 2 mar, Glenmark Generics, (GGI) USA, a subsidiary of Glenmark Generics (GGL), has received ANDA approval from the United States Food and Drug Administration (USFDA) for Ropinirole Hydrochloride tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg and 5 mg. Ropinirole Hydrochloride tablet is the generic version of GSK’s Requip® tablet in the US market. Total sales for Ropinirole Hydrochloride tablets in the twelve month period ending December 2009 were USD 104 million, as reported by IMS Health.
Valuation—
At current market price, stock is trading at 11.74 P/E multiple of its FY2011 Estimated earnings. We recommend investors to buy "Glenmark Pharmaceuticals limited" for medium term investment horizon.
Source: Internet (Valuenotes by Abhishek Jain)
No comments:
Post a Comment